Parker Waichman's Goldstein Takes Lead Role in GLP-1 NAION Litigation
Event summary
- Jason Goldstein of Parker Waichman LLP appointed Co-Chair of Plaintiffs' Executive Committee and Federal-State Court Liaison in MDL 3163 on February 23, 2026.
- MDL 3163 consolidates cases alleging GLP-1 drugs (Ozempic, Wegovy, Mounjaro, Zepbound) caused Non-Arteritic Anterior Ischemic Optic Neuropathy (NAION).
- NAION is a serious condition leading to sudden and irreversible blindness.
- Goldstein will coordinate federal and state proceedings nationwide.
The big picture
The appointment signals escalating legal challenges for GLP-1 drug manufacturers, a market segment valued at over $50 billion. The litigation could pressure companies to reassess risk disclosures and potentially impact prescribing patterns. The centralization of cases under MDL 3163 streamlines proceedings but also amplifies the collective legal threat.
What we're watching
- Litigation Scale
- How the pace of NAION-related case filings will impact the strategic focus of GLP-1 manufacturers.
- Regulatory Scrutiny
- Whether heightened litigation will prompt regulatory reviews of GLP-1 drug safety profiles.
- Manufacturer Response
- How pharmaceutical companies will adjust labeling, warnings, or clinical studies in response to the litigation.
Related topics